

2021 Women in Science
Fairleigh Dickinson University

Mini-Pharma on Your Desk: 3D Printing of Drug Delivery Systems for Women's Health

Hyunah Cho, Ph.D.

Assistant Professor of Pharmaceutical Sciences

School of Pharmacy and Health Sciences

Fairleigh Dickinson University

Women in Science

Association for Women in Science (<http://www.awis.org>)



My story




Why 3D printing

Flexible prototyping technology that has the potential to revolutionize the field of drug delivery.


Personalized medication



fixed-dose **combinations**



On-demand
medication



Opportunity to construct
complex geometry

First 3D-printed tablets

3D printing is a process of making an object from a digital file. This can be achieved in two ways, subtractive manufacturing and additive manufacturing.




In July 2015, FDA approved the first 3D printed tablets called **Spritam®** (levetiracetam) produced by Aprecia Pharmaceuticals. Spritam is a prescription medication used to treat partial onset seizures in patients 4 years of age and older with epilepsy, designed to ease of swallowing with just a sip of water.




ENABLING NEW CAPABILITIES IN PATIENT-CENTRIC THERAPY

Using an aqueous fluid to bind together multiple layers of powder, our unique, patent-protected 3DP technology platform¹ can be used to solve some of your toughest therapeutic challenges across multiple therapeutic areas.




-  **HIGHER DOSE LOADS**
Support dose loading up to 1,000 mg
-  **FAST-DISSOLVING**
Rapidly disintegrates on contact with liquid by breaking the bonds created during the 3DP process
-  **TASTE MASKING**
Allows the application of enhanced taste-masking techniques

ZipDose® Technology Using 3D Printing: How It's Made



First, a powdered medicine is spread into a thin layer.



Then, a liquid is dropped onto the powder.



This selectively binds the particles together in a thin, porous layer.



This process is repeated a specific number of times to add more layers based on the dosage, building the product from bottom to top.

The result is a porous drug product that disintegrates with just a sip of liquid.



www.Aprecia.com

1 Rectal suppositories containing artesunate

Malaria and children





Photo: Jaya Banerji/MMV




- 1,700 cases of malaria are reported yearly due to travelers and immigrants returning from countries with high malaria transmission rates, such as Africa and South Asia.
- Up to 80% of the children who live in rural areas die before reaching the hospital, due to lack of resources.
- At a community level, access to treatment (e.g., intramuscular injection (IM) artesunate) is still poor, ranging from hours to sometimes days. At this point, the disease may have progressed too far to be treated successfully.
- Rectal artesunate suppository is one of the options for pre-referral treatment of severe malaria, specifically in children under 6 years of age in remote areas.
- Rectal artesunate suppositories can treat young children who cannot take a medication orally due to vomiting or impaired consciousness and are pending transfer to a high-level facility where they can receive complete treatment.
- Rectal artesunate suppositories can treat young children who cannot take a medication orally due to vomiting or impaired consciousness. Single dose of 10 mg/kg artesunate should be given rectally.
- Rectocaps® formulated as 50-mg or 200-mg suppositories. Shelf-life is 24 months, should not be stored above 25°C and should avoid any excursions above 30°C.
- Besides artesunate's low solubility, obtaining the storage stability of the rectal suppositories at elevated temperatures (e.g., 30°C) is important.

Creating 3D-printed suppository shells




3D-printed PVA suppositories carrying artesunate

Physical properties




Height (mm)	Width (widest) (mm)	Orifice diameter (mm)	Shell thickness (mm)	Cavity diameter (mm)	Shell weight (g)	Artesunate (mg)
24.97 ± 0.01	8.35 ± 0.09	0.53 ± 0.03	1.23 ± 0.03	4.06 ± 0.07	0.71 ± 0.01	60 ± 1

Drug release





Thermostability (30°C, 35% RH, 6 h)



Types of suppositories	% Remaining	Visual appearance
PEG/free artesunate	90.0 ± 0.5	Soft/partially dissolved
3D-printed	100 ± 0.3	No change

Application: 3D printing of vaginal rings with personalized shapes for controlled release







Junhui Fu, Xiang Yu, Yiguang Jin, 3D printing of vaginal rings with personalized shapes for controlled release of progesterone, *International Journal of Pharmaceutics*, Volume 539, Issues 1–2, 2018, Pages 75–82, <https://doi.org/10.1016/j.ijpharm.2018.01.036>.

Future application focus on the feasibility of the 3D-printed “personalized PVA vaginal rings” for multi-drug delivery:

- Incorporation of one drug in the shell and another drug in the “tunnel” of the ring.
- Gradual/sequential delivery of multi-drugs.

2 Solid implants for multi-drug delivery

Customized nanogel discs




Application 1: Adjuvant ovarian cancer therapy



Peritoneal Surgery



Tumor removal



Treatment




Survival

Days Before surgery 1 3 7 14

Disk with
PTX/RAPA

Empty vehicle

Control




Formulation	Surgery + Disk with PTX/RAPA	Surgery+ Empty vehicle	Control (No surgery/ No treatment)
Median Survival (days)	30	21	14

Application 2: Post-surgical tumor detection




3 Solid implants for controlled drug release


Multi-layered “flexible” films



Drugs were mixed with low MW (12,000-16,000) or high MW (150,000) PLGA polymers. For the PLGA films carrying paclitaxel and rapamycin, a total of 60 mg of paclitaxel was added in the high MW PLGA mixture. A total of 60 mg of rapamycin was added in the low MW PLGA mixture.






Modeling using CAD software




Convert to Gcode

- Slice into layers
- Tell printer how to print each layer





Multi-layered PLGA films for controlled drug release

Physical properties



3D printing of bottom layer (A), rim layer (B), and core (C) of core-in-shell PLGA films carrying paclitaxel (core) and rapamycin (shell).




Representative images of single-layered (A), L/H/L (B), and core-in-shell PLGA films (C, D)

	Diameter (mm)	Weight (mg)	Paclitaxel (mcg)	Rapamycin (mcg)
Low	16 ± 0.5	15 ± 0.0	NA	396 ± 15
High	16 ± 0.3	14 ± 0.1	405 ± 21	NA
L/H/L	17 ± 0.5	45 ± 0.7	343 ± 13	749 ± 14
H/L/H	16 ± 0.3	48 ± 0.9	609 ± 12	352 ± 8
Core-in-Shell	16 ± 0.3	48 ± 0.8	315 ± 6	918 ± 23


Films	*Half-time (days)
Low (Rapamycin)	75
High (Paclitaxel)	57
L/H/L (Paclitaxel)	63
L/H/L (Rapamycin)	80
H/L/H (Paclitaxel)	56
H/L/H (Rapamycin)	74
Core-in-Shell (Paclitaxel)	54
Core-in-Shell (Rapamycin)	75

Application 1: Regional chemotherapy (e.g., ovarian, breast, and brain cancer)




- Chemotherapeutic agents generally have low BBB penetration
Local drug delivery needed
Accurate dosing needed
- Surgery often includes local implantation of Gliadel® wafers, biodegradable polymers containing 3.85% carmustine
Wafers are solid and inflexible
- Spatial constraints
Neurological tissue is sensitive increasing side-effects if not correctly shaped

Application 2: Pain relief (controlled of lidocaine)



	Diameter (mm)	Weight (mg)	Lidocaine (mcg)
Low	16 ± 0.1	16 ± 1	802 ± 12
High	16 ± 0.2	18 ± 1	800 ± 14
L/H/L	18 ± 0.5	52 ± 1	2408 ± 29
H/L/H	17 ± 0.8	50 ± 1	2309 ± 29
Core-in-Shell	17 ± 0.5	54 ± 1	2484 ± 28



Model	*Half-time (days)
Low (Lidocaine)	13
High (Lidocaine)	36
L/H/L (Lidocaine)	23
H/L/H (Lidocaine)	32
Core-in-Shell (Lidocaine)	22

● Low ■ High ▲ L/H/L
▼ H/L/H ■ Core-in-Shell

Ongoing: Making our own "INK" using recycled polymer (Sustainable science)



Women in Science

1. Be prepared, persistent, and resilient
2. Think strategically: find a niche
3. Pick your battles and do not be intimidated
4. Looking back and projecting ahead
5. Believe in yourself and your science: be confident and optimistic
- 6. Enjoy what you do!**

Acknowledgement

School of Pharmacy and Health Sciences, Fairleigh Dickinson University

FDU University Provost Seed Grant Program

Maryland Technology Development Corporation (TEDCO) Grant

OncoGone[®] LLC

FDU Student Researchers (Ioannis Serris, Panagiotis Serris, Suzanne Persaud, Sandra Eid, Natalia Swiderski, John Henaen)

Other FDU Student Researchers (Loyde Almirola, Serena Shammass, Kayla Paz, Jenna Sandomenico, Tyler Scgacger, Brielle Stawicki)

Newark Academy High school STEM Internship Program (Vikram Bala, Lillian Wu, Kaya Patel, Benjamin Chaddha, and Michael Wang)

Samuel Achilefu, Washington University in St. Louis

Udayabhanu Jammalamadaka, Washington University in St. Louis

Karthik Tappa, Washington University in St. Louis

Glen Kwon, University of Wisconsin-Madison



THANK YOU!

Questions? Interested in Joining us or Collaborations?

hyunahc@fdu.edu

Hyunah Cho, Ph.D
Assistant Professor
Pharmaceutical Sciences
School of Pharmacy and Health Sciences
Fairleigh Dickinson University

